<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03966014</url>
  </required_header>
  <id_info>
    <org_study_id>Amoxy 10-15</org_study_id>
    <nct_id>NCT03966014</nct_id>
  </id_info>
  <brief_title>Different Amoxicillin Treatment Regimens in Erythema Migrans Patients</brief_title>
  <official_title>Different Duration and Dosing of Amoxicillin in Patients With Erythema Migrans. A Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ljubljana School of Medicine, Slovenia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of different amoxicilline treatment
      regimens in patients with erythema migrans.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number (frequency) of patients with objective manifestations of Lyme borreliosis or subjective Lyme borreliosis-associated/post-Lyme borreliosis symptoms</measure>
    <time_frame>One year follow-up</time_frame>
    <description>At each visit physical examination wil be performed and clinical signs indicating objective manifestations of Lyme borreliosis, such as erythema migrans, will be searched for and documented. At each visit patients will be asked an open question about any health-related symptoms that had newly developed or worsened since the onset of erythema migrans. If these symptoms will have no other known medical explanation, they will be regarded as Lyme borreliosis-associated constitutional symptoms at enrolment or post-Lyme borreliosis symptoms at follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number (frequency) of patients with nonspecific symptoms</measure>
    <time_frame>One year follow-up</time_frame>
    <description>At each visit patients will be asked to complete a written questionnaire asking whether they had had any of eight non-speciﬁc symptoms (fatigue, arthralgias, headache,myalgias, paraesthesias, memory difﬁculties, concentration difﬁculties and irritability) within the preceding week.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">510</enrollment>
  <condition>Erythema Migrans</condition>
  <arm_group>
    <arm_group_label>EM-amoxicillin 3 x 10 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EM-amoxicillin 3 x 14 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EM-amoxicillin 2 x 14 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EM-amoxicillin 3 x 10 days</intervention_name>
    <description>Patients will receive amoxicillin 500 milligram tid for 10 days</description>
    <arm_group_label>EM-amoxicillin 3 x 10 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EM-amoxicillin 3 x 14 days</intervention_name>
    <description>Patients will receive amoxicillin 500 milligram tid for 14 days</description>
    <arm_group_label>EM-amoxicillin 3 x 14 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EM-amoxicillin 2 x 14 days</intervention_name>
    <description>Patients will receive amoxicillin 500 milligram bid for 14 days</description>
    <arm_group_label>EM-amoxicillin 2 x 14 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Controls</intervention_name>
    <description>No intervention.</description>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  erythema migrans

        Exclusion Criteria:

          -  pregnancy

          -  extracutaneous manifestations of Lyme borreliosis

          -  immunocompromising state

          -  serious adverse event to beta lactam antibiotic

          -  receiving antibiotic with antiborrelial activity within 10 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daša Stupica, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Infectious Diseases, University Medical Centre Ljubljana, Slovenia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daša Stupica, MD PhD</last_name>
    <phone>+38631689324</phone>
    <email>dasa.stupica@kclj.si</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maša Velušček, MD</last_name>
    <phone>+38631332904</phone>
    <email>masa.veluscek@kclj.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Centre Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daša Stupica, MD, PhD</last_name>
      <phone>+386 31 689 324</phone>
      <email>dasa.stupica@kclj.si</email>
    </contact>
    <contact_backup>
      <last_name>Maša Velušček, MD</last_name>
      <phone>+386 31 332 904</phone>
      <email>masa.veluscek@kclj.si</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daša Stupica, MD, PhD</last_name>
      <phone>+386 31 689 324</phone>
      <email>dasa.stupica@kclj.si</email>
    </contact>
    <contact_backup>
      <last_name>Maša Velušček, MD</last_name>
      <phone>+386 31 332 904</phone>
      <email>masa.veluscek@kclj.si</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Daša Stupica</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythema Chronicum Migrans</mesh_term>
    <mesh_term>Glossitis, Benign Migratory</mesh_term>
    <mesh_term>Erythema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

